2022 World Conference on Lung Cancer (ePosters)-EP09.01-002. Patient with Immune-associated Dermatomyositis Caused byAdvanced NSCLC Treated with ICIs

EP09.01-002. Patient with Immune-associated Dermatomyositis Caused byAdvanced NSCLC Treated with ICIs

Pdf Summary

This case report discusses the treatment and nursing care of a patient with immune-associated dermatomyositis caused by advanced non-small cell lung cancer (NSCLC) who was treated with immune checkpoint inhibitors (ICIs). The patient received anti-PD-1 antibody intravenously along with oral anrotinib. However, the patient experienced immune-related adverse events (irAEs) including liver dysfunction, muscle weakness, pain in the extremities, generalized skin flushing, and oral and pharyngeal pain. The patient's condition was considered grade IV and potentially life-threatening. High-dose methylprednisolone sodium succinate shock therapy was administered, which resulted in significant improvement in liver function and cardiac enzymes. The irAEs were determined to be definitely related to anti-PD-1 antibodies and possibly related to Anrotinib hydrochloride, so these medications were permanently discontinued. The patient also developed a white film formation in the sputum, which was treated with aggressive antifungal therapy. With targeted care, the patient's symptoms, signs, and laboratory tests improved, and the patient was discharged after 22 days with improvement in all areas. The report emphasizes the importance of early identification, reporting, and treatment of irAEs, as well as continuous monitoring and care for complications. This case provides valuable insights for the clinical care of irAEs, aiming to improve the treatment outcomes for NSCLC patients.

Asset Subtitle

Yuanyong Wang

Meta Tag

Speaker Yuanyong Wang

Topic Nursing and Allied Health Professionals

Keywords

immune-associated dermatomyositis

non-small cell lung cancer

immune checkpoint inhibitors

anti-PD-1 antibody

irAEs

liver dysfunction

muscle weakness

skin flushing

antifungal therapy

NSCLC patients